Navigation Links
Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference
Date:11/3/2009

ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 15-19, 2009 in Boston, Massachusetts. Presentations are listed below.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

  • Poster Session: Monday, November 16, 2009 - 12:30 p.m. - 2:30 p.m. Abstract No.: A106, "A Phase 1 study of ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML)," Halls C-D, 2nd floor.
  • Poster Session: Monday, November 16, 2009 - 12:30 p.m. - 2:30 p.m. Abstract No.: A156, "Mechanisms of resistance to Aurora kinase B inhibitors in leukemia: development and characterization of in vitro models," Halls C-D, 2nd floor.
  • Poster Session: Wednesday, November 18, 2009 - 12:30 p.m. - 2:30 p.m. Abstract No: C75, "A novel multi-targeted Aurora A and VEGFR2 kinase inhibitor, ENMD-2076, demonstrates synergistic antiproliferative and proapoptotic effects in combination with chemotherapy and trastuzumab in breast cancer cell lines," Halls C-D, 2nd floor.

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrate significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic t
'/>"/>

SOURCE EntreMed
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. EntreMed Focuses on Development of ENMD-2076
2. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
3. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
4. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
5. Success of Shape Up Somerville childhood obesity intervention to be presented
6. Survival data presented from phase II study of hormone-resistant prostate cancer patients
7. Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai
8. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
9. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
10. Horizons AMI trial data to be presented at TCT 2007
11. AMIHOT II trial data presented at TCT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... in benign prostate tissue was associated with high-grade, ... found even in those with low prostate-specific antigen ... Cancer Epidemiology, Biomarkers & Prevention , a ... , An analysis of prostate tissue biopsies collected ... the Prostate Cancer Prevention Trial (PCPT) found that ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... Consumer demand for healthy lifestyle drives new store openings, ... new year means,a new resolution or two. For GNC, ... the supplement industry is expected to rise steadily,through 2012, ... time for GNC to once again expand its store ...
... Phase 2 Clinical Trials,Dow AgroSciences CEO Discusses Future Opportunities ... Sangamo BioSciences, Inc.,(Nasdaq: SGMO ) announced that the ... and preview objectives for 2008 during its,annual Investor and ... Jerome Peribere, President and CEO of Dow AgroSciences will ...
... a division of Wyeth (NYSE: WYE ), ... leading scientific and pharmaceutical,achievements at the third annual ... 4. Wyeth received honors for Best Overall Pipeline, ... by Scrip World Pharmaceutical News,a leading source of ...
... -- Apart from a more complicated medical case, ... time with their patients" Researchers at UC Davis ... that affect the length of a patients medical ... the doctors visit. , In a new ...
... Drug has significant risks, and its benefits are still debated, ... U.S. Food and Drug Administration advisory panel recommended Wednesday that ... women with advanced breast cancer. , In a close vote, ... the growth of tumors did not outweigh the increased risk ...
... two Phase III clinical trials support that Asacol, an ... agents known as 5-aminosalicylic acids (5-ASAs), is an effective ... ulcerative colitis (UC), including isolated proctitis. The results ... dosed at 2.4 g/day for six weeks, experienced significant ...
Cached Medicine News:Health News:GNC Franchising Expected to Grow Through 2008 2Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 2Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 3Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 4Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 5Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 6Health News:Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives 7Health News:Wyeth Receives Honors at the 2007 Scrip Awards 2Health News:Wyeth Receives Honors at the 2007 Scrip Awards 3Health News:Wyeth Receives Honors at the 2007 Scrip Awards 4Health News:Wyeth Receives Honors at the 2007 Scrip Awards 5Health News:New UC Davis study finds physician style and HMO affiliation impact lengths of patient visit 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 3Health News:Asacol treats UC symptoms of isolated proctitis 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner ... Summit , May 14-16, 2014 at the Global Center ... . This is the premier industry ... achievements through open innovation. Participants will learn how world-changing ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 21 More than one in three diabetes ... prescribed, stating that they have done so on average three ... estimate that in reality this number could be as high ... and Physicians in Insulin Therapy (GAPP™) survey, released today by ...
... WESTLAKE VILLAGE, Calif., Sept. 21 As consumer ... on overall pharmacy customer satisfaction has increased considerably ... Associates 2010 U.S. National Pharmacy Study(SM) released today. ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20050527/LAF028LOGO-a ) The ...
Cached Medicine Technology:New Global Survey Reveals Over One in Three Patients Fail to Take Insulin as Prescribed 2New Global Survey Reveals Over One in Three Patients Fail to Take Insulin as Prescribed 3J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 2J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 3J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 4J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 5
... duet Signature Series multipurpose gamma camera ... imaging applications. The system uniquely combines the ... features and flexibility of modern day SPECT ... e.cam duet maximizes camera performance ...
... ANGIO CT MIYABI system is ... SOMATOM CT scanner on rails ... Multistar angiography unit. Both systems ... table, which can be switched ...
... The Allura Xper FD10 supports the ... concept that allows personalization of personalized user ... at tableside in one intuitive user interface. ... 3D-RA and StentBoost can be controlled from ...
... The STARFlex is a fourth generation ... CardioSEAL by the addition of a unique ... coil micro-spring. The micro-spring is attached to ... and provides a self-adjusting positioning mechanism which ...
Medicine Products: